- Home
- LAES vs RDHL Comparison
LAES vs RDHL Comparison
Compare LAES & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LAES | RDHL |
|---|---|---|
| Founded | 2022 | 2009 |
| Country | Switzerland | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.2M | 3.8M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | LAES | RDHL |
|---|---|---|
| Price | $2.49 | $0.80 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 6.5M | 21.8K |
| Earning Date | 03-31-2026 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $93.36 | $381.91 |
| Revenue Next Year | $43.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $0.71 |
| 52 Week High | $8.71 | $3.31 |
Technical Indicators
Market Signals| Indicator | LAES | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 30.93 | 39.01 |
| Support Level | N/A | N/A |
| Resistance Level | $2.88 | $0.90 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 20.43 | 47.02 |
Price Performance
Historical ComparisonAbout LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.